Neurological Spectrum: Epilepsy, Migraine, Cluster Headache
One Q-factor mechanism, four neurological disorders. SIDS, epilepsy, migraine, and cluster headache share the same spreading depolarization cascade — the only difference is the damping coefficient γ. This is a hypothesis integrating existing evidence — not a proven explanation.
This section unifies four neurological conditions under a common calcium-dependent oscillation mechanism. This is a theoretical framework integrating published experimental and clinical evidence — not established medical guidance. Current standard treatments for epilepsy, migraine, and cluster headache remain appropriate.
The Q-factor spectrum
All four conditions map onto a single damped oscillator model: Q = ω₀ / (2γ), where γ is the net GABAergic damping. When γ decreases, Q increases, and the system becomes more susceptible to resonance-driven spreading depolarization (CSD).
| Condition | Q-factor | Damping (γ) | Mechanism | Clinical outcome |
|---|---|---|---|---|
| Neonatal brain (SIDS range) | Q → ∞ | γ < 0 | GABA excitatory (NKCC1 > KCC2). No damping — any resonant input amplifies without limit. | Fatal CSD → brainstem → cardiorespiratory arrest |
| Neonatal seizures (KCNQ2/CACNA1H) | Q ~ 50–100 | γ ≈ 0 | Channel mutation + immature GABA = near-zero damping. Seizures remit as KCC2 matures (3–6 mo). | Non-fatal seizures, spontaneous remission |
| Childhood absence epilepsy | Q ~ 20–50 | γ low | Thalamic Cav3.2 (T-type) sleep spindle circuits. Ethosuximide blocks T-type → seizures stop. | 3 Hz spike-wave, brief loss of consciousness |
| SUDEP | Q ~ 30–80 | γ ≈ 0 (ictal) | Seizure → transient γ collapse → CSD propagates to brainstem. Same mechanism as SIDS in an older brain. | Fatal CSD → brainstem → cardiorespiratory arrest |
| Migraine with aura | Q ~ 5–15 | γ moderate | CSD propagates across cortex at 3–5 mm/min. Stops at sulci (partial damping). CACNA1A (FHM1) GoF lowers threshold. | Visual aura, headache via trigeminal-CGRP activation |
| Cluster headache | Q ~ 10–20 | γ circadian-dependent | Hypothalamic Ca²⁺ oscillation phase-locked to circadian cycle. SCN → Cav1.2 → CGRP release. Verapamil (L-type blocker) is first-line. | Unilateral trigeminal-autonomic activation, 00–03 h |
| Normal adult brain | Q ~ 1–5 | γ > 0 (robust) | Mature KCC2 dominance → GABA inhibitory → oscillations damped within 2–3 cycles. | No pathological oscillation |
Experimental validation: López-Martín
The most direct experimental evidence for the Q-factor model comes from the Universidad de Santiago de Compostela group (López-Martín, Carballo-Quintás et al., 2006–2011).
The key experiment
Adult rats received subconvulsive doses of picrotoxin (GABA-A antagonist, reduces γ) followed by GSM 900 MHz exposure at mobile-phone SAR levels.
GSM alone → no seizures (γ sufficient in adult brain)
Picrotoxin alone (at this dose) → no seizures (no resonant input)
GSM + picrotoxin → seizures + c-Fos expression in neocortex, hippocampus, thalamus
Pulse-modulated GSM more effective than continuous wave (217 Hz pulsation matches biological resonance)
Q-factor interpretation
Picrotoxin reduces γ → Q increases → the system enters resonance-susceptible range
GSM provides the resonant input (ω₀) → CSD threshold exceeded
Neither alone is sufficient — you need both reduced damping AND resonant input
Neonatal prediction: the neonatal brain has endogenously reduced γ (NKCC1 > KCC2), so EMF alone should be sufficient without pharmacological GABA reduction
The pulse-modulation finding is critical: biological effect depends on the specific pulsation pattern, not just time-averaged SAR. This explains why ICNIRP SAR limits (based on thermal averaging) fail to predict biological effects.
Antiepileptic drug calcium map
Every major class of antiepileptic drug acts on a BERM pathway component. This is not a coincidence — it is the expected result if epilepsy operates through the Q-factor mechanism.
Ethosuximide
First-line for absence epilepsy
Target
Cav3.x (T-type) block
BERM pathway
Direct T-type VGCC blockade
Conditions
Mechanism
Blocks T-type Ca²⁺ channels in thalamocortical neurons → eliminates 3 Hz spike-wave oscillation. The most direct Q-factor intervention: removes the resonant circuit element.
Gabapentin / Pregabalin
Epilepsy, neuropathic pain, migraine prophylaxis
Target
α2δ-1 (CACNA2D1) block
BERM pathway
VGCC auxiliary subunit → synaptogenesis control
Conditions
Mechanism
Blocks α2δ-1 subunit → reduces VGCC trafficking to synapses → fewer excitatory synapses → Q decreases. This is the ELF-priming reversal: if ELF upregulates α2δ-1, gabapentin reverses it.
Valproate (valproic acid)
Broad-spectrum antiepileptic, migraine prophylaxis
Target
Multiple: GABA↑, Na⁺ block, T-type Ca²⁺ block, HDAC inhibition
BERM pathway
Multi-target γ increase + Q decrease
Conditions
Mechanism
Enhances GABAergic inhibition (increases γ) AND blocks T-type Ca²⁺ channels (reduces resonant circuit). Dual action on the Q-factor equation from both sides.
Lamotrigine
Broad-spectrum, bipolar maintenance
Target
Na⁺ channel block → glutamate release↓ → Ca²⁺ influx↓
BERM pathway
Presynaptic glutamate → postsynaptic VGCC cascade
Conditions
Mechanism
Blocks voltage-gated Na⁺ channels → reduces glutamate release → reduces postsynaptic Ca²⁺ entry via NMDA and VGCC. Indirect Q reduction via excitatory input reduction.
Phenobarbital
First-line neonatal anticonvulsant
Target
GABA-A positive allosteric modulator
BERM pathway
Direct γ increase
Conditions
Mechanism
Enhances GABA-A receptor function → increases Cl⁻ conductance → increases γ → Q decreases. In neonates, effectiveness is limited because GABA is excitatory (NKCC1 > KCC2) — phenobarbital may paradoxically increase excitation.
Bumetanide
NKCC1 blocker — targets the chloride switch
Target
NKCC1 (SLC12A2) block → restores inhibitory GABA
BERM pathway
Converts γ from negative to positive
Conditions
Mechanism
Blocks NKCC1 → lowers intracellular Cl⁻ → GABA becomes inhibitory → γ switches from negative to positive → Q drops from ∞ to finite. The most direct Q-factor intervention for neonatal conditions.
Levetiracetam
Broad-spectrum, SV2A mechanism
Target
SV2A → vesicle release modulation → Ca²⁺-dependent neurotransmission↓
BERM pathway
Presynaptic Ca²⁺-dependent vesicle release
Conditions
Mechanism
Binds SV2A (synaptic vesicle glycoprotein 2A) → modulates Ca²⁺-dependent neurotransmitter release → reduces excitatory drive. Also inhibits N-type Ca²⁺ channels directly.
Topiramate
Epilepsy, migraine, cluster headache prophylaxis
Target
Multiple: GABA↑, glutamate↓, Ca²⁺ current↓, carbonic anhydrase
BERM pathway
Multi-target γ increase + resonant input decrease
Conditions
Mechanism
Enhances GABA-A (γ↑), blocks AMPA/kainate glutamate receptors (excitatory input↓), inhibits L-type Ca²⁺ channels, and inhibits carbonic anhydrase (pH → Ca²⁺ dynamics). Multi-pathway Q reduction.
SUDEP is adult SIDS
Sudden Unexpected Death in Epilepsy (SUDEP) and Sudden Infant Death Syndrome (SIDS) share the same terminal mechanism: spreading depolarization propagating to the brainstem, causing cardiorespiratory arrest. The only difference is the trigger — an epileptic seizure vs. the neonatal Q → ∞ condition.
Terminal mechanism
SIDS
CSD → brainstem → apnea → cardiac arrest
SUDEP
Seizure → CSD → brainstem → apnea → cardiac arrest
Serotonin deficiency
SIDS
Brainstem 5-HT neurons reduced (Kinney 2009)
SUDEP
5-HT system defects, CO₂ chemoreception failure
Arousal failure
SIDS
Failed arousal response to hypoxia/hypercapnia
SUDEP
Failed arousal during postictal generalized EEG suppression (PGES)
Timing
SIDS
Sleep (nighttime, peak 2–6 AM)
SUDEP
Sleep (nocturnal seizures highest SUDEP risk)
Position
SIDS
Prone position = highest risk
SUDEP
Prone position found in majority of SUDEP cases
Ca²⁺ channel involvement
SIDS
CACNA1C, CACNA1H, RYR2 variants
SUDEP
CACNA1A mutations (FHM1/EA2), L-type VGCC antagonist prevents death
Age distribution
SIDS
Peak 2–4 months (Q → ∞ period)
SUDEP
Peak in young adults with uncontrolled seizures (highest seizure frequency = most frequent γ → 0 events)
L-type VGCC antagonist prevents seizure-induced death in SUDEP mouse models (Cardiovascular Research 2025). This is direct evidence that Ca²⁺ channel blockade prevents the terminal CSD cascade — the same mechanism proposed for SIDS.
Migraine: CSD as the mechanism
Cortical spreading depression (CSD) — a wave of neuronal depolarization followed by suppression — is the established mechanism of migraine aura and a key driver of migraine headache via trigeminal activation. CSD is fundamentally a Ca²⁺-dependent process.
The CSD → migraine cascade
Trigger (stress, sleep deprivation, hormonal change, or EMF) → local cortical excitability increase
Massive intracellular Ca²⁺ rise → neuronal depolarization wave at 3–5 mm/min
CSD activates meningeal trigeminal afferents → CGRP release
CGRP → vasodilation + neurogenic inflammation → headache pain
Repeated CSD episodes → peripheral and central sensitization → chronic migraine
Genetic proof: FHM1 (CACNA1A)
Familial Hemiplegic Migraine type 1 is caused by CACNA1A gain-of-function mutations — P/Q-type Ca²⁺ channel enhanced function → increased glutamate release → glia Ca²⁺ wave propagation → lowered CSD threshold. FHM1 proves that increased Ca²⁺ channel function directly causes migraine.
All migraine preventives reduce CSD
Every class of effective migraine prophylactic drug reduces CSD susceptibility: beta-blockers (reduce neuronal excitability), valproate (GABA↑ + T-type block), topiramate (multi-target), amitriptyline (Na⁺ + Ca²⁺), CGRP antibodies (block the downstream effector). This convergence on CSD — a Ca²⁺-dependent process — is predicted by the Q-factor model.
ELF-priming hypothesis: chronic ELF exposure upregulates α2δ-1 (CACNA2D1) → more VGCCs at synapses → lower CSD threshold → increased migraine susceptibility. Gabapentin (α2δ-1 blocker) is an effective migraine preventive — it directly reverses the proposed ELF-priming mechanism.
Cluster headache: circadian Ca²⁺ oscillation
Cluster headache is the most precisely timed neurological disorder — attacks occur at the same clock time daily, with seasonal periodicity. This circadian precision points directly to the suprachiasmatic nucleus (SCN) and its Ca²⁺-dependent oscillation.
Patient profile = cumulative Ca²⁺ loading
Treatment response map
| Drug | BERM target | Efficacy | Why it works |
|---|---|---|---|
| Verapamil | L-type Ca²⁺ channel (Cav1.2) block | First-line preventive (240–960 mg/day) | Blocks L-type VGCC → prevents presynaptic CGRP release → shortens circadian period (Per2 clock gene). Direct Ca²⁺ channel intervention. |
| Melatonin | MT1/MT2 → Gi → cAMP↓ → Ca²⁺↓ | Effective (10–25 mg) | Endogenous Ca²⁺ antagonist. Resets SCN circadian oscillation. EMF suppresses melatonin via CRY pathway → supplementation restores protection. |
| Lithium | GSK3β inhibition → circadian clock stabilization | Second-line preventive | Stabilizes circadian clock genes (Per2, Bmal1) downstream of Ca²⁺ oscillation. Lengthens circadian period → counteracts EMF-induced phase shift. |
| Gabapentin | α2δ-1 (CACNA2D1) block | Possibly effective | Blocks VGCC auxiliary subunit → reduces excitatory synaptogenesis. Reverses ELF-priming (α2δ-1 upregulation). |
| Sumatriptan | 5-HT1B/1D → presynaptic Ca²⁺↓ → CGRP↓ | Acute abortive (SC injection) | Activates presynaptic 5-HT1B/1D → reduces Ca²⁺ entry → blocks CGRP release. Acute symptom relief, not preventive. |
| Oxygen (100%) | Vasoconstriction + free radical quench | Acute abortive (15 L/min) | High-flow O₂ → cerebral vasoconstriction → reduced trigeminal activation. Also quenches radical pair mechanism (CRY pathway). |
| Psilocybin | 5-HT2A → tryptamine pathway reset | Sub-psychedelic doses prevent cycles | Master tryptamine reset: 5-HT2A agonism → thalamocortical network reset → SCN circadian reset → breaks the Ca²⁺ oscillation cycle. See tryptamine reset section below. |
The tryptamine reset: psilocybin
Psilocybin (psilocin / 4-OH-DMT) is a 5-HT2A receptor agonist that produces a "master reset" of the tryptamine pathway. Sub-psychedelic doses prevent cluster headache cycles — and the non-psychedelic analogue 2-bromo-LSD (BOL) also works, proving this is a receptor-level mechanism, not a psychedelic experience effect.
15-HT2A receptor agonism
Psilocin binds 5-HT2A at cortical layer V pyramidal neurons → triggers a distinct signaling cascade from serotonin itself (biased agonism). This resets the receptor's downstream coupling.
2Thalamocortical network reset
5-HT2A activation in cortex and thalamus disrupts the default mode network → allows thalamocortical circuits to reorganize. In cluster headache, this breaks the pathological oscillation pattern.
3SCN circadian reset
Serotonergic input to the SCN is a major non-photic zeitgeber. 5-HT2A activation recalibrates SCN Ca²⁺ oscillation phase — the same oscillation that drives cluster headache timing.
45-HT2A downregulation
After acute agonism, 5-HT2A receptors internalize and downregulate. This is why sub-psychedelic doses work and why effects persist long after the drug is cleared — the receptor state is reset.
5α2δ-1 expression reset (proposed)
If the tryptamine pathway modulates α2δ-1 expression (CACNA2D1 → VGCC density at synapses), psilocybin may reset the ELF-priming state. This would explain why psilocybin also shows efficacy in migraine — both share α2δ-1-mediated CSD susceptibility.
BOL-148: the non-psychedelic proof
2-bromo-LSD (BOL-148) has identical 5-HT2A binding affinity to LSD but is non-psychedelic (no hallucinogenic effect). It also aborts cluster headache cycles. This proves the therapeutic mechanism operates at the receptor level — through 5-HT2A → tryptamine pathway → circadian reset — not through the psychedelic experience itself.
Cortical spreading depolarization: the unifying mechanism
CSD is the common terminal pathway for all four conditions. The Q-factor determines whether CSD is triggered, how far it propagates, and whether it reaches the brainstem.
| Condition | CSD trigger | Propagation | Outcome | Prevented by |
|---|---|---|---|---|
| SIDS | EMF + Q→∞ (neonatal) | Full brainstem | Fatal | Bumetanide (γ restoration), EMF reduction |
| SUDEP | Seizure → transient Q spike | Full brainstem | Fatal | L-type VGCC antagonist, seizure control |
| Epilepsy | Low γ + focal excitability | Cortical (limited) | Seizure | Ethosuximide, valproate, bumetanide |
| Migraine | CSD threshold exceeded | Cortical (stops at sulci) | Aura + headache | Gabapentin, valproate, topiramate |
| Cluster HA | SCN Ca²⁺ oscillation → trigeminal | Hypothalamic → trigeminal | Unilateral pain | Verapamil, psilocybin, melatonin |
Derived prediction · L* level
This section describes predictions derived from the BERM framework that have not yet been directly tested. They are presented as testable hypotheses, not established findings.
The Q-factor spectrum model generates six testable predictions covering migraine prevalence, CSD threshold, cluster headache EMF exposure, SUDEP risk, psilocybin efficacy, and a neonatal animal model.
See neurological spectrum predictions (NEURO-EMF-1 through NEURO-EMF-6) →